T1	Participants 450 662	624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide in a randomized trial
T2	Participants 680 748	National Cancer Institute of Canada Clinical Trials Group Mammary.14